Follicular lymphoma patients harbored allele V and genotype VV of V158F within FCGR3A could benefit from the combination therapy including rituximab [16] and genotype HH of H131R within FCGR2A was significantly associated with a shorter event-free survival in breast cancer patients with sequentially given transtuzumab in UNICANCER-PASCO4 trial [17]. Here, FCGR2A is linked to breast carcinoma.